We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

63 hedge funds and large institutions have $129M invested in Autolus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

31% more funds holding

Funds holding: 48 → 63 (+15)

15% more capital invested

Capital invested by funds: $113M → $129M (+$16.8M)

9.72% more ownership

Funds ownership: 24.11% → 33.82% (+9.7%)

Holders
63
Holders Change
+15
Holders Change %
+31.25%
% of All Funds
1.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
20
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$15.9M
2
OM
Opaleye Management
Massachusetts
+$15.6M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.5M
4
IC
Ikarian Capital
Texas
+$9.3M
5
Capital International Investors
Capital International Investors
California
+$7.77M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$5.1M
2
BBA
Baker Bros. Advisors
New York
-$2.37M
3
EP
Eversept Partners
New York
-$1.39M
4
GIM
Granahan Investment Management
Massachusetts
-$924K
5
Victory Capital Management
Victory Capital Management
Texas
-$541K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
$17K +$10.9K +1,468 +91%
LC
52
Lindbrook Capital
California
$17K +$17.7K +2,393 +394%
SFS
53
Sowell Financial Services
Arkansas
$8K +$11.1K +1,500 New
CFGS
54
Concourse Financial Group Securities
Alabama
$6K – – –
TCWM
55
Total Clarity Wealth Management
Illinois
$6K +$7.4K +1,000 New
Citigroup
56
Citigroup
New York
$4K -$2.71K -366 -36%
PCM
57
Penserra Capital Management
California
$4K -$185 -25 -3%
US Bancorp
58
US Bancorp
Minnesota
$4K +$962 +130 +24%
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$2K +$1.2K +162 +142%
ED
60
Exane Derivatives
France
$1.03K – – –
Barclays
61
Barclays
United Kingdom
$1K -$429 -58 -39%
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
$1K +$1.07K +145 New
Franklin Resources
63
Franklin Resources
California
– -$5.1M -570,455 Closed
EP
64
Eversept Partners
New York
– -$1.39M -154,981 Closed
MB
65
MPM BioImpact
Massachusetts
– -$355K -39,740 Closed
BCM
66
Burrage Capital Management
Massachusetts
– -$134K -15,006 Closed
PA
67
Parallel Advisors
California
– -$2K -229 Closed
1 2
3

AUTL Hedge Fund Activity: Q1 2021 in Review

63 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2021, worth a combined $129M — up 15% from $113M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new AUTL positions and 6 closed out — a net gain of 16 holders — while 20 added to existing stakes and 10 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $15.9M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.1M sold.

  • 63 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2021, up from 48 in Q4 2020.
  • Funds reported $129M of Autolus Therapeutics stock for Q1 2021, up 15% quarter-over-quarter.
  • 22 funds opened new Autolus Therapeutics positions in Q1 2021 and 6 closed out, a net change of +16 holders.
  • The largest Autolus Therapeutics buyer in Q1 2021 was Deerfield Management, an estimated $15.9M added.
  • The largest Autolus Therapeutics seller in Q1 2021 was Franklin Resources, an estimated $5.1M sold.

Based on aggregated 13F filings for Q1 2021.